Evidence map›Paper›PMID 22006347›Full record

Trial reportEuropean journal of clinical pharmacology2012

Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia.

Irena Loryan, Marja Lindqvist, Inger Johansson, Masahiro Hiratsuka, Ilse van der Heiden, Ron H N van Schaik, Jan Jakobsson, Magnus Ingelman-Sundberg

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of clinical pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Association BetweenPharmacogenomics and personalized medicine · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Pharmacogenomics and personalized medicine · 2022
    Article
  16. Review
  17. Article
  18. The Effect ofPharmacogenomics and personalized medicine · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Irena LoryanSection of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE-171 77, Stockholm, Sweden.
Marja Lindqvist
Inger Johansson
Masahiro Hiratsuka
Ilse van der Heiden
Ron H N van Schaik
Jan Jakobsson
Magnus Ingelman-Sundberg

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe basis of high intersubject variability of propofol metabolism is unclear. Therefore, we examined the influence of genetic polymorphisms of the key metabolizing enzymes cytochrome P450 2B6 (CYP2B6) and uridine diphosphate (UDP)-glucuronosyltransferase 1A9 (UGT1A9), age, and sex on propofol biotransformation in vitro and in vivo.

methodsPlasma concentrations of propofol, 4-hydroxypropofol, and their glucuronides were measured over 20 min in 105 patients after a single intravenous bolus of propofol. Propofol 4-hydroxylation activity, genotypes, and content of CYP2B6 protein in 68 human livers were determined. The common single nucleotide polymorphisms (SNPs) for the CYP2B6 and UGT1A9 genes were analyzed by polymerase chain reaction (PCR).

resultsPlasma levels of propofol metabolites showed high interindividual variability (range of coefficient of variation 89-128%). This was supported by in vitro data showing similar variability of propofol 4-hydroxylation in liver microsomes and 1.9-fold higher CYP2B6 protein content in the livers from women. No significant relationships were revealed between the SNPs studied and propofol metabolism. However, patients' sex had a pronounced effect on propofol metabolism. Thus, women had higher amounts of propofol glucuronide (1.25-fold; p = 0.03), 4-hydroxypropofol-1-glucuronide (2.1-fold; p = 0.0009), and 4-hydroxypropofol-4-glucuronide (1.7-fold; p = 0.02) as shown by the weight-corrected area under the time-plasma concentration curve of metabolites. Additionally, the sexual dimorphism in 4-hydroxypropofol glucuronidation was prominent in the 35- to 64-year-old subgroup.

conclusionsNo significant effects of CYP2B6 and UGT1A9 SNPs or age on propofol metabolism were revealed in this pilot study, but there was a pronounced effect of sex, a finding that indicates an important factor for the previously described sex difference in systemic clearance of propofol seen.

Indexed as

AdolescentAdultAgedAnesthetics, IntravenousAryl Hydrocarbon HydroxylasesCytochrome P-450 CYP2B6FemaleGlucuronosyltransferaseHumansLiverMaleMiddle AgedOxidoreductases, N-DemethylatingPolymorphism, Single NucleotidePropofolSex FactorsAnesthetics, IntravenousAryl Hydrocarbon HydroxylasesCYP2B6 protein, humanCytochrome P-450 CYP2B6GlucuronosyltransferaseOxidoreductases, N-DemethylatingPropofolUDP-Glucuronosyltransferase 1A9UGT1A9 protein, human

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.